<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30220107</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2045-7634</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>7</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer medicine</Title>                <ISOAbbreviation>Cancer Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors.</ArticleTitle>            <Pagination>                <MedlinePgn>4952-4963</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.1754</ELocationID>            <Abstract>                <AbstractText>We examined the incidence of cardiovascular disease (CVD) among 32 757 cancer survivors and age-, gender-, and geographically matched cancer-free controls during a follow-up period of 1-13 years, and explored whetherCVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1-year cancer survivors without a history ofCVD diagnosed with breast (n = 6762), prostate (n = 4504), non-Hodgkin (n = 1553), Hodgkin (n = 173), lung and trachea (n = 2661), basal cell carcinoma (BCC; n = 12 476), and colorectal (n = 4628) cancer during 1999-2011 were selected from the Netherlands Cancer Registry and matched to cancer-free controls without a history ofCVD. Drug dispenses and hospitalizations from thePHARMO Database Network were used as proxy forCVD. Data were analyzed using Cox regression analyses. Prostate (HR: 1.17; 95%CI: 1.01-1.35) and lung and trachea (HR: 1.48; 95%CI: 1.10-1.97) cancer survivors had an increased risk for developingCVD compared to cancer-free controls. This increased risk among lung and trachea cancer survivors remained statistically significant after including traditional cardiovascular risk factors and cancer treatment information (HR: 1.41; 95%CI: 1.06-1.89). Among prostate cancer survivors, the increased risk of incidentCVD was limited to those who received hormones and those without traditional cardiovascular risk factors. Breast, non-Hodgkin,BCC, and colorectal cancer survivors showed no increasedCVD risk compared to cancer-free controls. There was an increased risk of incidentCVD among prostate, and lung and trachea cancer survivors compared to age-, gender- and geographically matched cancer-free controls. Studies including longer follow-up periods are warranted to examine whether cancer survivors are at increased risk of long-term incidentCVD.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Schoormans</LastName>                    <ForeName>Dounya</ForeName>                    <Initials>D</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4476-2747</Identifier>                    <AffiliationInfo>                        <Affiliation>CoRPS - Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical psychology, Tilburg University, Tilburg, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vissers</LastName>                    <ForeName>Pauline A J</ForeName>                    <Initials>PAJ</Initials>                    <AffiliationInfo>                        <Affiliation>CoRPS - Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical psychology, Tilburg University, Tilburg, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>van Herk-Sukel</LastName>                    <ForeName>Myrthe P P</ForeName>                    <Initials>MPP</Initials>                    <AffiliationInfo>                        <Affiliation>PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Denollet</LastName>                    <ForeName>Johan</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>CoRPS - Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical psychology, Tilburg University, Tilburg, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pedersen</LastName>                    <ForeName>Susanne S</ForeName>                    <Initials>SS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Southern Denmark, Odense, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dalton</LastName>                    <ForeName>Susanne O</ForeName>                    <Initials>SO</Initials>                    <AffiliationInfo>                        <Affiliation>Survivorship Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rottmann</LastName>                    <ForeName>Nina</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Southern Denmark, Odense, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>National Research Center for Cancer Rehabilitation, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>van de Poll-Franse</LastName>                    <ForeName>Lonneke</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>CoRPS - Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical psychology, Tilburg University, Tilburg, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Southern Denmark, Odense, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>UVT2013-5893</GrantID>                    <Agency>Social Psychology Fellowship from the Dutch Cancer Society</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer Med</MedlineTA>            <NlmUniqueID>101595310</NlmUniqueID>            <ISSNLinking>2045-7634</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Nov;166(1):259-266</RefSource>                <PMID Version="1">28717854</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2015 Dec 5;386(10010):2257-74</RefSource>                <PMID Version="1">26382241</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Oncol. 2006 Jun;33(3 Suppl 8):S2-7</RefSource>                <PMID Version="1">16781283</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1993 Jun 16;85(12):979-87</RefSource>                <PMID Version="1">8496983</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2008 Jun 1;112(11 Suppl):2577-92</RefSource>                <PMID Version="1">18428205</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Res Nurs. 2014 Oct;16(4):448-55</RefSource>                <PMID Version="1">25199652</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 1999 Apr 27;99(16):2192-217</RefSource>                <PMID Version="1">10217662</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Intern Med. 2015 Jun;175(6):1007-17</RefSource>                <PMID Version="1">25915855</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2000 Jan 7;100(1):57-70</RefSource>                <PMID Version="1">10647931</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2004 Apr;30(2):181-91</RefSource>                <PMID Version="1">15023436</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Oncol. 2007;46(4):417-32</RefSource>                <PMID Version="1">17497308</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Sci (Lond). 2011 May;120(10):427-40</RefSource>                <PMID Version="1">21271986</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Drugs. 2010 Jul;21(6):578-90</RefSource>                <PMID Version="1">20375725</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Med. 2018 Oct;7(10):4952-4963</RefSource>                <PMID Version="1">30220107</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Oncol Hematol. 2010 Dec;76(3):196-207</RefSource>                <PMID Version="1">20036574</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Heart J. 2012 Jul;33(13):1635-701</RefSource>                <PMID Version="1">22555213</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2007 Mar 7;99(5):365-75</RefSource>                <PMID Version="1">17341728</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2006 Apr 1;107(7):2912-9</RefSource>                <PMID Version="1">16339404</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):423-8</RefSource>                <PMID Version="1">10519163</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):510-6</RefSource>                <PMID Version="1">17372246</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2010 Jan;46(2):395-404</RefSource>                <PMID Version="1">19811904</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2013 Jan;104(1):9-14</RefSource>                <PMID Version="1">23066889</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Behav Immun. 2011 Mar;25(3):555-64</RefSource>                <PMID Version="1">21182930</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2006 Sep 20;24(27):4448-56</RefSource>                <PMID Version="1">16983113</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Apr 1;34(10):1122-30</RefSource>                <PMID Version="1">26834065</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychooncology. 2010 Feb;19(2):141-9</RefSource>                <PMID Version="1">19382112</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">cancer survivors</Keyword>            <Keyword MajorTopicYN="N">cardiotoxic treatment</Keyword>            <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>            <Keyword MajorTopicYN="N">matched cohort study</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30220107</ArticleId>            <ArticleId IdType="doi">10.1002/cam4.1754</ArticleId>            <ArticleId IdType="pmc">PMC6198235</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>